Access and Evidence
Payers and the ABCs of digital literacy
Convincing payers of the value of digital add-ons and of drug/device combinations requires pharma to demonstrate that patients and other stakeholders understand how to use them
More Access and Evidence Articles
Access and Evidence
Decoding the patient journey with RWD
Patient real-world data contains a wealth of potentially valuable information for life sciences commercial teams, if they can filter out the noise
Access and Evidence
Keeping it real: How data is driving healthcare reform in China
China’s healthcare market is ripe for those capable of helping it capture the vast potential of real-world data
Access and Evidence
Including the caregiver in access submissions
Partnering with caregivers can help build a more powerful case for re-imbursement if pharma can gather the right evidence
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Access and Evidence
Survey results: Accelerating digital transformation during COVID-19
View the results of a survey of over 1000 pharma executives on the impact COVID-19 has had and will have on their operations
Access and Evidence
A burning desire to make a difference for patients
Annexus Health, eyeforpharma’s 2020 Health Start-up winner is on a mission for patients
Access and Evidence
From reactive to predictive: Concerto’s new compositions
Artificial Intelligence has only just begun to unlock high value innovation. The latest predictive tools will break new ground, says Concerto HealthAI’s Jeff Elton
Access and Evidence
Evolving HTA frameworks to accelerate innovation
Iterative evidence generation and demonstrating value over time could help unlock delays in getting cures out, saving more lives, says Janssen’s Clare Hague